Are calcium channel blockers protective against first-dose reactions to OKT3? 1992

E A Richard, and M I Lorber, and W H Marks, and M J Bia
Department of Medicine, Yale University School of Medicine, New Haven, CT 06510.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016853 Muromonab-CD3 Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti). Monoclonal Antibody OKT3,OKT3,Orthoclone OKT3,Muromonab CD3

Related Publications

E A Richard, and M I Lorber, and W H Marks, and M J Bia
September 2014, Asian Pacific journal of allergy and immunology,
E A Richard, and M I Lorber, and W H Marks, and M J Bia
March 1996, The Journal of allergy and clinical immunology,
E A Richard, and M I Lorber, and W H Marks, and M J Bia
April 1993, Transplantation proceedings,
E A Richard, and M I Lorber, and W H Marks, and M J Bia
January 2023, Drug target insights,
E A Richard, and M I Lorber, and W H Marks, and M J Bia
January 1985, British journal of clinical pharmacology,
E A Richard, and M I Lorber, and W H Marks, and M J Bia
August 2016, Cardiovascular drugs and therapy,
E A Richard, and M I Lorber, and W H Marks, and M J Bia
October 1995, Biochemical pharmacology,
E A Richard, and M I Lorber, and W H Marks, and M J Bia
June 2016, Journal of the American Geriatrics Society,
E A Richard, and M I Lorber, and W H Marks, and M J Bia
October 1994, Drugs & aging,
E A Richard, and M I Lorber, and W H Marks, and M J Bia
April 1989, Archives of internal medicine,
Copied contents to your clipboard!